We are live on ! Find out more
ALXO icon

ALX Oncology

105 hedge funds and large institutions have $510M invested in ALX Oncology in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

295% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $400K

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

13% more funds holding

Funds holding: 93 → 105 (+12)

0.58% less ownership

Funds ownership: 91.86% → 91.28% (-0.58%)

2% less capital inflows, than outflows

Capital inflows: $37.9M | Capital outflows: $38.8M

13% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 31

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
105
Holders Change
+12
Holders Change %
+12.9%
% of All Funds
1.51%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
21
Increased
27
Reduced
31
Closed
9
Calls
$1.58​M
Puts
$400​K
Net Calls
+$1.18​M
Net Calls Change
-⁠$1.67​M

ALXO Hedge Fund Activity: Q1 2024 in Review

105 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2024, worth a combined $510M — down 25% from $681M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ALXO positions and 9 closed out — a net gain of 12 holders — while 27 added to existing stakes and 31 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $13.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $13.6M sold.

  • 105 institutional investors held ALX Oncology (ALXO) as of Q1 2024, up from 93 in Q4 2023.
  • Funds reported $510M of ALX Oncology stock for Q1 2024, down 25% quarter-over-quarter.
  • 21 funds opened new ALX Oncology positions in Q1 2024 and 9 closed out, a net change of +12 holders.
  • The largest ALX Oncology buyer in Q1 2024 was Vestal Point Capital, an estimated $13.4M added.
  • The largest ALX Oncology seller in Q1 2024 was Point72 Asset Management, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2024.